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OBJECTIVES: To compare divalproex sodium and valproic acid
for therapeutic patterns, persistence rates, and predictors of 
hospitalization among bipolar patients on monotherapy in the
Veterans Affairs Health care system. METHODS: Using VA
administrative data bases, we conducted a retrospective incep-
tion cohort study of VA patients’ °Y´ 18 years of age who had at
least one outpatient diagnoses of bipolar disorder and two con-
tinuous prescription records for the study drugs in the VA PBM
pharmacy database during the study period of April 1, 2001 to
September 30 2003. Persistence for the comparative drugs was
reported as continuous variable and compared using t-tests.
Logistic regression models were used to examine the risk of hos-
pitalization whereas Cox proportional hazard regression models
were used to evaluate the time to hospitalization and time to
interruption of therapy for the two drug groups. RESULTS: We
identiﬁed 4, 624 bipolar patients on monotherapy with valproic
acid (n = 4036) and divalproex sodium (n = 588) during the
study period. The descriptive statistics included sociodemo-
graphics, disability and comorbidity status and were similar for
the two groups. For the crude persistence rates there were no sta-
tistically signiﬁcant differences between divalproex sodium (120
days) and valproic acid (110 days). The logistic regression model
for risk of hospitalization showed no statistically signiﬁcant dif-
ference between the two comparators (OR = 1.06, 95% CI =
0.787–1.444). The Cox model for time to interruption of therapy
showed an insigniﬁcant hazard ratio for divalproex sodium
versus valproic acid (HR = 0.928, 95% CI = 0.844–1.020) and
for time to hospitalization also no statistically signiﬁcant differ-
ence in the hazard ratio for the two drugs (HR = 0.984, 95% CI
= 0.784–1.295). CONCLUSION: The study showed a compa-
rable proﬁle of generic valproic acid with divalproex sodium for
persistence and predictors of hospitalization for bipolar patients
on monotherapy in the VA. Results have important health care
implications for treatment and costs.
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OBJECTIVES: Given the high incidence of post-stroke depres-
sion (PSD), its serious sequalae, and inherent problems with
diagnosis, prophylactic use of antidepressants may be a viable
management strategy in patients experiencing stroke. The
purpose of this study was to assess the prophylactic effects 
of antidepressants in non-depressed patients with stroke.
METHODS: A meta-analysis of randomized placebo-controlled
trials (RCTs) evaluating the prophylactic effects of antidepres-
sants in non-depressed patients with stroke was conducted. Lit-
erature searches in MEDLINE, PubMed, CINAHL, PsycINFO,
EMBASE, Cochrane library, and CNKI from 1950 to August
2006 were used to identify the relevant studies. Outcome mea-
sures included the occurrence rate of newly developed PSD cases
and severity of depressive symptoms as indicated by mean
depression rating scales scores. The effect size was presented as
rate difference (RD) or weighted mean difference (WMD).
RESULTS: From 10 RCTs, a total of 703 non-depressed patients
after stroke were identiﬁed. The pooled occurrence rate of newly
developed PSD cases in the intervention and control groups were
12.54% (41/327) and 29.17% (91/312), respectively (pooled RD
= −0.17, 95% CI: −0.26 to −0.08). Prophylactic effects of anti-
depressants were not related to duration of use (coefﬁcient of
Pearson’ correlation [ã] = 0.57, p = 0.11). CONCLUSION: Anti-
depressant prophylaxis is associated with a signiﬁcant reduction
in the occurrence rate of newly developed PSD, suggesting anti-
depressants may be considered along with other vascular pre-
ventive strategies in management of stroke patients.
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OBJECTIVES: With 50–70% antipsychotic prescriptions
written for off-label purposes, the objective of this study is to
explore the pattern and the outcomes of adverse events (ADEs)
associated with antipsychotic off-label use. METHODS: A ret-
rospective pharmaco-vigilance analysis was conducted using the
FDA Adverse Event Reporting System (AERS) data between
April 2004 and March 2006. ADE cases associated with antipsy-
chotic medications were ﬁrst identiﬁed based on the role of the
medication in precipitating the ADEs (primary and secondary
suspects) and then categorized according to their intended indi-
cations as off-label/on-label uses. Thereafter, the most frequently
reported off-label antipsychotic uses associated with ADEs were
explored, and their clinical outcomes were examined and com-
pared with on-label antipsychotic ADE cases. RESULTS: Out of
27,700 ADEs involving antipsychotic medications, antipsy-
chotics were the primary suspect in 7519 cases and secondary
suspect in 2409 cases (Total: 9928). Atypical antipsychotics
accounted for majority of the cases (9122, 91.8%) with clozap-
ine (2983, 30.1%) being the most frequently reported antipsy-
chotic medication followed by quetiapine (2186, 22.0%) and
risperidone (2153, 21.7%). Off-label use afﬂicted half of the
reported ADEs cases (4767, 48%). The top three reported off-
label indications associated with ADEs include psychotic and
schizoaffective disorders (1372, 28.8%), mood disorders (1105,
23.2%) and cognitive disorders (406, 8.5%). These ADEs could
result into severe clinical outcomes. Of total 4767 ADEs associ-
ated with off-label use, (1942, 40.7%) involved hospitalizations
and (1043, 21.9% ) deaths. Similar pattern of clinical outcomes
were found in ADE cases associated with on-label antipsychotic
use. CONCLUSION: Most of the off-label antipsychotic-related
ADEs reported to FDA is associated with using atypical antipsy-
chotic medications for treating schizoaffective disorder, bipolar
disorder, depression and dementia. More than half of these ADEs
resulted in severe clinical outcomes such as hospitalizations and
death. Therefore, the risk beneﬁt ratio should be seriously con-
sidered when physicians prescribe antipsychotics for off-label
purposes.
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OBJECTIVES: To compare the risk of treatment-emergent dia-
betes (TED) in schizophrenic patients treated with atypical
(AAP) versus typical antipsychotic (TAP) medications.
METHODS: We conducted a retrospective database analysis on
episodes of care initiated after 1/1/2000 using data from Medi-
Cal. Our analysis included episodes for patients 18 years of age
or older, diagnosed with schizophrenia, who switched medica-
tions after a minimum “wash out” period of 15 days and had
no evidence of diabetes in the previous 6 months. We used a
simultaneous bivariate probit model to estimate the risk of TED
in patients treated with AAP in comparison to TAP. If the error
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terms in the treatment selection equation and the TED equation
proved to be independent we re-estimated by univariate probit.
Sensitivity analyses estimating the effect of olanzapine, risperi-
done and quetiapine independently versus TAP were also con-
ducted. RESULTS: A Wald test of the correlation coefﬁcient of
the disturbances suggests that treatment selection is exogenous
in our model (rho = −0.049 (p = 0.57)) using a Huber-White
sandwich estimator of the variance. The univariate probit para-
meter estimates of AAP is statistically signiﬁcantly positive (p =
0.044) suggesting that AAP are associated with an increased risk
of TED relative to TAP. The marginal effect of AAP is 0.0827;
that is the TED propensity of AAP is 8.27% higher than that of
TAP. A univariate probit model demonstrated that olanzapine (p
= 0.10), quetiapine (p = 0.10) and risperidone (p = 0.31) were
independently associated with an increased risk of TED, though
not signiﬁcantly. A bivariate probit model omitting prior comor-
bidity, drug use and quarterly dummy variables demonstrates
selection bias (rho = −0.650 (p = 0.0029)). CONCLUSION: The
results of this study show that AAP are associated with an
increased risk of TED relative to TAP. Evidence of unobserved
selection bias was not present. Explanatory variables that may
explain treatment selection that were included in our model were
sufﬁcient to control for choice of therapy.
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OBJECTIVES: The association between suicidality and antide-
pressant use has been reported in literature using clinical trial
data. This study 1) investigates the relationship between suici-
dality and antidepressants use in children and adolescents using
managed care claims data; 2) examines the effect of an FDA
black box warning on antidepressant use in children and ado-
lescents. METHODS: Subjects 5–19 years old, continuously
enrolled in a large Midwestern IPA model health plan, diagnosed
with depression (using ICD-9-CM codes) or issued at least one
antidepressant prescription between January 1, 2004 and June
30, 2005 were included in the study. Descriptive statistics, paired
samples t-test, Chi-Square test, and stepwise logistic regression
were used to analyze the data. RESULTS: A total of 5104 sub-
jects (7.2% continuously enrolled in 5–19 year olds) met the
study criteria; 53% female; mean age was 15 years; 67% had
depression diagnosis. Antidepressant use was modestly associ-
ated with suicidality using Chi-square test (x2 = 3.03, p = 0.08;
contingency odds ratio = 1.67). Logistic regression showed that
antidepressant use is not a signiﬁcant predictor to suicidality,
while gender, depression diagnosis, other comorbid mental
health, drug and alcohol abuse, and specialty provider were sig-
niﬁcant predictors to suicidality. While average days on antide-
pressant drug therapy decreased signiﬁcantly (p = 0.009) after
the black box warning, the number of inpatient stays for depres-
sion after the black box warning increased signiﬁcantly (p =
0.007). CONCLUSION: From this claims database, the associ-
ation between suicidality and antidepressant use in children and
adolescents is not clear. Caution is needed in the use of antide-
pressants in this population. Increased inpatient stays following
the black box warning may be an indication that providers are
more aware of the suicidality risk or due to decreased use of anti-
depressants. It is important to balance appropriate usage and
concerns for the safety of medications with the risk of adverse
events and subsequent health service use.
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FORECASTING U.S. MEDICAID PROGRAM EXPENDITURE ON
ANTIDEPRESSANT DRUGS
Ferrand YB, Kelton CM, Levy MS, Guo JJ
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OBJECTIVES: Depression is the most prevalent major mental
health disorder, affecting between eight and ten percent of the
U.S. population. The U.S. Medicaid programs spent approxi-
mately $2 billion on antidepressant drugs in 2005, across three
categories of antidepressants including selective serotonin reup-
take inhibitors, tricyclic antidepressants, and other antidepres-
sants. Predicting future prices and utilization of antidepressants
would facilitate Medicaid’s planning process. Our objective is to
build forecasting models that can be used to improve Medicaid’s
budgeting efforts. METHODS: We gather quarterly data
(1991–2004, Centers for Medicare & Medicaid Services) on
Medicaid national antidepressant expenditure. We use Box-
Jenkins forecasting techniques on expenditure and utilization
time series for speciﬁc antidepressants including Paxil, Prozac,
Wellbutrin and Zoloft. Intervention analysis is used to determine
the effects of patent expiration, new branded-drug entry, and
new indication approval. Forecasts are computed and compared
to a holdout sample, comprised of the 2005 data, to assess the
performance of the models. RESULTS: The Box-Jenkins ARIMA
algorithms for ﬁtting and diagnosing the expenditure and uti-
lization data resulted in four distinct non-stationary forecasting
models. Final models were selected using standard information-
based criteria. The Paxil and Prozac models incorporated an
intervention term corresponding to patent expiration: a step
function for Paxil and an exponential decay for Prozac. The best
ﬁtting model for Wellbutrin is a third order moving average in
the ﬁrst differences; the Zoloft model is a Random Walk.
Maximum likelihood was used for estimations. Usual checks on
the residuals proved to be satisfactory. CONCLUSION: ARIMA
modeling can be used to capture the time series of individual
antidepressant drugs purchased by Medicaid. Moreover, inter-
vention analysis can be used to demonstrate the effect that
generic entry has on the utilization of or expenditure on a
branded medication. We ﬁnd that the drugs studied are affected
differently by this type of event.
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OBJECTIVES: To analyze, from a payer perspective, the net
beneﬁt of prescribing divalproex sodium extended-release
(DVPX-ER) versus valproic acid (VPA) in patients who suffer
from bipolar disorder. METHODS: The study used a decision
analytic framework to compare the net beneﬁt of DVPX-ER rel-
ative to VPA in the treatment of bipolar disease. The decision
model incorporated on two primary outcomes: GI side effects,
and treatment success. Levels of health service utilization and
probability values were obtained from an expert panel comprised
of 15 psychiatrists. Costs were obtained from an academic
medical center. Two-way sensitivity analysis on the probability
of GI events and the probability of disease control for VPA was
used to provide further insight regarding the set of combinations
of values in the model consistent with the decision to use VPA
and DVPX-ER. RESULTS: The average probability of GI side
